Topological data analysis identifies molecular phenotypes of idiopathic pulmonary fibrosis
暂无分享,去创建一个
[1] Ivana V. Yang,et al. Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis , 2021, Thorax.
[2] P. Skipp,et al. Identification of proteins associated with development of metastasis from cutaneous squamous cell carcinomas (cSCCs) via proteomic analysis of primary cSCCs * , 2020, The British journal of dermatology.
[3] P. Spagnolo,et al. Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis , 2020, Internal and Emergency Medicine.
[4] T. Greulich,et al. Transcriptional analysis identifies potential biomarkers and molecular regulators in pneumonia and COPD exacerbation , 2020, Pneumologie.
[5] C. Auffray,et al. IL-17-high asthma with features of a psoriasis immunophenotype. , 2019, The Journal of allergy and clinical immunology.
[6] Hyun J. Kim,et al. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry , 2019, Respiratory Research.
[7] C. Auffray,et al. Stratification of asthma phenotypes by airway proteomic signatures. , 2019, The Journal of allergy and clinical immunology.
[8] C. Auffray,et al. Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma. , 2019, Respiratory medicine.
[9] Takeshi Johkoh,et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.
[10] Anthony Rowe,et al. A computational framework for complex disease stratification from multiple large-scale datasets , 2018, BMC Systems Biology.
[11] C. Auffray,et al. A Severe Asthma Disease Signature from Gene Expression Profiling of Peripheral Blood from U‐BIOPRED Cohorts , 2017, American journal of respiratory and critical care medicine.
[12] C. Greenwood,et al. Novel insights into systemic autoimmune rheumatic diseases using shared molecular signatures and an integrative analysis , 2017, Epigenetics.
[13] Xinxin Zhang,et al. Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis , 2017, Scientific Reports.
[14] Anthony Atala,et al. Common pathway signature in lung and liver fibrosis , 2016, Cell cycle.
[15] G. Song,et al. Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis. , 2016, Cell stem cell.
[16] N. Burke,et al. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada , 2016, European Respiratory Journal.
[17] P. Boor,et al. The role of PDGF-D in healthy and fibrotic kidneys. , 2016, Kidney international.
[18] Xiaobing Fu,et al. Epithelial-mesenchymal transition: An emerging target in tissue fibrosis , 2016, Experimental biology and medicine.
[19] R. Hubbard,et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review , 2015, European Respiratory Journal.
[20] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[21] I. Noth,et al. The mitochondrial cardiolipin remodeling enzyme lysocardiolipin acyltransferase is a novel target in pulmonary fibrosis. , 2014, American journal of respiratory and critical care medicine.
[22] T. Bein,et al. Medical nanoparticles for next generation drug delivery to the lungs , 2014, European Respiratory Journal.
[23] A. Suzuki,et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis , 2014, Hepatology.
[24] George C Tseng,et al. Peripheral Blood Mononuclear Cell Gene Expression Profiles Predict Poor Outcome in Idiopathic Pulmonary Fibrosis , 2013, Science Translational Medicine.
[25] Andreas Heider,et al. virtualArray: a R/bioconductor package to merge raw data from different microarray platforms , 2013, BMC Bioinformatics.
[26] Joyce S Lee,et al. A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis , 2012, Annals of Internal Medicine.
[27] I. Noth,et al. Profiling Of Gene Expression In Idiopathic Pulmonary Fibrosis , 2012, Asian Test Symposium.
[28] S. Sahn,et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.
[29] H. Collard,et al. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.
[30] Kun Wu,et al. Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. , 2010, Cancer research.
[31] Bei-fang Ning,et al. Hepatocyte nuclear factor 4α attenuates hepatic fibrosis in rats , 2009, Gut.
[32] K. Korach,et al. Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis. , 2008, American journal of respiratory cell and molecular biology.
[33] A. Gressner,et al. Pro-fibrogenic potential of PDGF-D in liver fibrosis. , 2007, Journal of hepatology.
[34] F. Martinez,et al. The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis , 2005, Annals of Internal Medicine.
[35] A. Pardo,et al. Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.
[36] N. Kohno,et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. , 1998, American journal of respiratory and critical care medicine.
[37] Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.
[38] A. Azuma,et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , 2015 .
[39] S. Rosselot. Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[40] D. Schroeder,et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. , 2010, Chest.